Migraine attacks are classified into prodrome (premonitory), aura, headache, and postdrome phases. Over the past three decades, treatments have primarily targeted the headache phase. A recent clinical trial focused on alleviating prodromal symptoms using ubrogepant, a small-molecule calcitonin gene-related peptide antagonist in 1,087 individuals. The study found that more patients treated with ubrogepant reported an absence of photophobia (19.5% vs. 12.5%), fatigue (27.3% vs. 16.8%), neck pain (28.9% vs. 15.9%), phonophobia (50.7% vs.
35.8%), dizziness (88.5% vs. 82.3%), difficulty concentrating (8.7% vs. 2.1%), and difficulty thinking (56.9% vs. 41.8%), compared to those receiving placebo. Notably, the effects of ubrogepant were observed as early as one hour after administration. Additionally, fewer patients who received ubrogepant required rescue medication within 24 hours (21.7% vs.…
